Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

LOS ANGELES–(BUSINESS WIRE)–The FDA has granted Orphan Drug Designation to Puma Biotechnology’s drug candidate alisertib for the treatment of small cell lung cancer.
Click here to view original post